Japanese Journal of Ophthalmology

, Volume 57, Issue 3, pp 301–307 | Cite as

Visual outcome of photodynamic therapy for typical neovascular age-related macular degeneration and polypoidal choroidal vasculopathy over 5 years of follow-up

  • Akiko Miki
  • Shigeru Honda
  • Hiroshi Kojima
  • Masaya Nishizaki
  • Tomoko Nagai
  • Masashi Fujihara
  • Mamoru Uenishi
  • Mihori Kita
  • Yasuo Kurimoto
  • Akira Negi
  • Hyogo Macular Disease Study Group
Clinical Investigation

Abstract

Purpose

To evaluate the long-term effects of photodynamic therapy (PDT) on typical neovascular age-related macular degeneration (tAMD) and polypoidal choroidal vasculopathy (PCV).

Methods

This was a multicenter prospective study of 139 eyes from 136 patients (tAMD: 74 eyes; PCV: 65 eyes) who underwent PDT as the initial treatment. The change in best-corrected visual acuity (BCVA), predictive factors for the BCVA at 60 months, frequency of recurrence, and mean recurrence period were analyzed.

Results

The pre-PDT BCVA and greatest linear dimension (GLD) did not differ between the two groups. The mean BCVA (logMAR) was significantly improved at 6 months post-initial PDT (post-PDT) in the PCV group (−0.11, P = 0.0091). However, at 60 months post-PDT, the mean BCVA was significantly worse than baseline in the tAMD (+0.21, P = 0.0035) and PCV (+0.21, P = 0.0076) groups. Pre-PDT BCVA, age, and GLD were the factors significantly associated with the BCVA at 60 months post-PDT. Although the frequency of recurrence did not significantly differ between the two phenotype groups, the mean recurrence period was significantly longer in the PCV group than in the tAMD group (15.7 vs. 8.6 months, P = 0.0020).

Conclusions

PDT may not have benefits for visual acuity in cases of tAMD and PCV over 5 years of follow-up.

Keywords

Long-term outcome Photodynamic therapy Age-related macular degeneration Polypoidal choroidal vasculopathy Multicenter study 

References

  1. 1.
    Cook HL, Patel PJ, Tufail A. Age-related macular degeneration: diagnosis and management. Br Med Bull. 2008;85:127–49.PubMedCrossRefGoogle Scholar
  2. 2.
    Ding X, Patel M, Chan CC. Molecular pathology of age-related macular degeneration. Prog Retin Eye Res. 2009;28:1–18.PubMedCrossRefGoogle Scholar
  3. 3.
    Yannuzzi LA, Sorenson J, Spaide RF, Lipson B. Idiopathic polypoidal choroidal vasculopathy (IPCV). Retina. 1990;10:1–8.PubMedCrossRefGoogle Scholar
  4. 4.
    Uyama M, Matsubara T, Fukushima I, Matsunaga H, Iwashita K, Nagai Y, et al. Idiopathic polypoidal choroidal vasculopathy in Japanese patients. Arch Ophthalmol. 1999;117:1035–42.PubMedCrossRefGoogle Scholar
  5. 5.
    Yannuzzi LA, Ciardella A, Spaide RF, Rabb M, Freund KB, Orlock DA. The expanding clinical spectrum of idiopathic polypoidal choroidal vasculopathy. Arch Ophthalmol. 1997;115:478–85.PubMedCrossRefGoogle Scholar
  6. 6.
    Spaide RF, Yannuzzi LA, Slakter JS, Sorenson J, Orlach DA. Indocyanine green videoangiography of idiopathic polypoidal choroidal vasculopathy. Retina. 1995;15:100–10.PubMedCrossRefGoogle Scholar
  7. 7.
    Ciardella AP, Donsoff IM, Huang SJ, Costa DL, Yannuzzi LA. Polypoidal choroidal vasculopathy. Surv Ophthalmol. 2004;49:25–37.PubMedCrossRefGoogle Scholar
  8. 8.
    Maruko I, Iida T, Saito M, Nagayama D, Saito K. Clinical characteristics of exudative age-related macular degeneration in Japanese patients. Am J Ophthalmol. 2007;144:15–22.PubMedCrossRefGoogle Scholar
  9. 9.
    Yannuzzi LA, Negrao S, Iida T, Carvalho C, Rodriguez-Coleman H, Slakter J, et al. Retinal angiomatous proliferation in age-related macular degeneration. Retina. 2001;21:416–34.PubMedCrossRefGoogle Scholar
  10. 10.
    Boscia F, Parodi MB, Furino C, Reibaldi M, Sborgia C. Photodynamic therapy with verteporfin for retinal angiomatous proliferation. Graefes Arch Clin Exp Ophthalmol. 2006;244:1224–32.PubMedCrossRefGoogle Scholar
  11. 11.
    Krebs I, Krepler K, Stolba U, Goll A, Binder S. Retinal angiomatous proliferation: combined therapy of intravitreal triamcinolone acetonide and PDT versus PDT alone. Graefes Arch Clin Exp Ophthalmol. 2008;246:237–43.PubMedCrossRefGoogle Scholar
  12. 12.
    Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T, ANCHOR Study Group. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology. 2009;116:57–65.PubMedCrossRefGoogle Scholar
  13. 13.
    Bressler NM, Chang TS, Fine JT, Dolan CM, Ward J, Anti-VEGF Antibody for the Treatment of Predominantly Classic Choroidal Neovascularization in Age-Related Macular Degeneration (ANCHOR) Research Group. Improved vision-related function after ranibizumab vs photodynamic therapy: a randomized clinical trial. Arch Ophthalmol. 2009;127:13–21.PubMedCrossRefGoogle Scholar
  14. 14.
    Matsumiya W, Honda S, Bessho H, Kusuhara S, Tsukahara Y, Negi A. Early responses to intravitreal ranibizumab in typical neovascular age-related macular degeneration and polypoidal choroidal vasculopathy. J Ophthalmol. 2011;742020. doi:10.1155/2011/742020.
  15. 15.
    Tsujikawa A, Ooto S, Yamashiro K, Tamura H, Otani A, Yoshimura N. Treatment of polypoidal choroidal vasculopathy by intravitreal injection of bevacizumab. Jpn J Ophthalmol. 2010;54:310–9.PubMedCrossRefGoogle Scholar
  16. 16.
    Gomi F, Sawa M, Sakaguchi H, Tsujikawa M, Oshima Y, Kamei M, et al. Efficacy of intravitreal bevacizumab for polypoidal choroidal vasculopathy. Br J Ophthalmol. 2008;92:70–3.PubMedCrossRefGoogle Scholar
  17. 17.
    Stangos AN, Gandhi JS, Nair-Sahni J, Heimann H, Pournaras CJ, Harding SP. Polypoidal choroidal vasculopathy masquerading as neovascular age-related macular degeneration refractory to ranibizumab. Am J Ophthalmol. 2010;150:666–73.PubMedCrossRefGoogle Scholar
  18. 18.
    Chan WM, Lam DS, Lai TY, Liu DT, Li KK, Yao Y, et al. Photodynamic therapy with verteporfin for symptomatic polypoidal choroidal vasculopathy. Ophthalmology. 2004;111:1576–84.PubMedCrossRefGoogle Scholar
  19. 19.
    Akaza E, Yuzawa M, Matsumoto Y, Kashiwakura S, Fujita K, Mori R. Role of photodynamic therapy in polypoidal choroidal vasculopathy. Jpn J Ophthalmol. 2007;51:270–7.PubMedCrossRefGoogle Scholar
  20. 20.
    Gomi F, Ohji M, Sayanagi K, Sawa M, Sakaguchi H, Oshima Y, et al. One-year outcomes of photodynamic therapy in age-related macular degeneration and polypoidal choroidal vasculopathy in Japanese patients. Ophthalmology. 2008;115:141–6.PubMedCrossRefGoogle Scholar
  21. 21.
    Kurashige Y, Otani A, Sasahara M, Yodoi Y, Tamura H, Tsujikawa A, et al. Two-year results of photodynamic therapy for polypoidal choroidal vasculopathy. Am J Ophthalmol. 2008;146:513–9.Google Scholar
  22. 22.
    Honda S, Imai H, Yamashiro K, Kurimoto Y, Kanamori-Matsui N, Kagotani Y, et al. Comparative assessment of photodynamic therapy for typical age-related macular degeneration and polypoidal choroidal vasculopathy: a multicenter study in Hyogo prefecture, Japan. Ophthalmologica. 2009;223:333–8.PubMedCrossRefGoogle Scholar
  23. 23.
    Honda S, Kurimoto Y, Kagotani Y, Yamamoto H, Takagi H, Uenishi M, Hyogo Macular Disease Study Group. Photodynamic therapy for typical age-related macular degeneration and polypoidal choroidal vasculopathy: a 30-month multicenter study in Hyogo, Japan. Jpn J Ophthalmol. 2009;53:593–7.PubMedCrossRefGoogle Scholar
  24. 24.
    Kaiser PK, Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: 5-year results of two randomized clinical trials with an open-label extension: TAP report no. 8. Graefes Arch Clin Exp Ophthalmol. 2006;244:1132–42.Google Scholar
  25. 25.
    Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin. One-year results of 2 randomized clinical trials: TAP report 1. Arch Ophthalmol. 1999;117:1329–45.Google Scholar
  26. 26.
    Verteporfin in Photodynamic Therapy Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization: verteporfin in photodynamic therapy report 2. Am J Ophthalmol. 2001;131:541–60.CrossRefGoogle Scholar
  27. 27.
    Fung AE, Lalwani GA, Rosenfeld PJ, Dubovy SR, Michels S, Feuer WJ, et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol. 2007;143:566–83.PubMedCrossRefGoogle Scholar
  28. 28.
    Potter MJ, Szabo SM. Recurrence of choroidal neovascularisation after photodynamic therapy in patients with age-related macular degeneration. Br J Ophthalmol. 2007;91:753–6.PubMedCrossRefGoogle Scholar
  29. 29.
    Koh A, Lee WK, Chen LJ, Chen SJ, Hashad Y, Kim H, et al. EVEREST STUDY: efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy. Retina. 2012;32:1453–64.PubMedCrossRefGoogle Scholar
  30. 30.
    Heier JS, Boyer DS, Ciulla TA, Ferrone PJ, Jumper JM, Gentile RC, FOCUS Study Group, et al. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS Study [published correction appears in Arch Ophthalmol. 2007;125:138]. Arch Ophthalmol. 2006;124:1532–42.PubMedCrossRefGoogle Scholar
  31. 31.
    Antoszyk AN, Tuomi L, Chung CY, Singh A, FOCUS Study Group. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration (FOCUS): year 2 results. Am J Ophthalmol. 2008;145:862–74.PubMedCrossRefGoogle Scholar
  32. 32.
    Hara R, Kawaji T, Inomata Y, Tahara J, Sagara N, Fukushima M, et al. Photodynamic therapy alone versus combined with intravitreal bevacizumab for neovascular age-related macular degeneration without polypoidal choroidal vasculopathy in Japanese patients. Graefes Arch Clin Exp Ophthalmol. 2010;248:931–6.PubMedCrossRefGoogle Scholar
  33. 33.
    Bressler NM, Treatment of Age-Related Macular Degeneration with Photodynami Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2. Arch Ophthalmol. 2001;119:198–207.Google Scholar
  34. 34.
    Bessho H, Honda S, Imai H, Negi A. Natural course and funduscopic findings of polypoidal choroidal vasculopathy in a Japanese population over 1 year of follow-up. Retina. 2011;31:1598–602.PubMedCrossRefGoogle Scholar

Copyright information

© Japanese Ophthalmological Society 2013

Authors and Affiliations

  • Akiko Miki
    • 1
  • Shigeru Honda
    • 1
  • Hiroshi Kojima
    • 2
  • Masaya Nishizaki
    • 3
  • Tomoko Nagai
    • 4
  • Masashi Fujihara
    • 5
  • Mamoru Uenishi
    • 5
  • Mihori Kita
    • 6
    • 7
  • Yasuo Kurimoto
    • 2
  • Akira Negi
    • 1
  • Hyogo Macular Disease Study Group
  1. 1.Department of Surgery, Division of OphthalmologyKobe University Graduate School of MedicineKobeJapan
  2. 2.Department of OphthalmologyKobe City General HospitalKobeJapan
  3. 3.Department of OphthalmologyOno Municipal HospitalOnoJapan
  4. 4.Department of OphthalmologySteel Memorial Hirohata HospitalHimejiJapan
  5. 5.Department of OphthalmologyMitsubishi Kobe HospitalKobeJapan
  6. 6.Department of OphthalmologyHyogo Prefectural Amagasaki HospitalAmagasakiJapan
  7. 7.Department of OphthalmologyNational Hospital Organization Kyoto Medical CenterKyotoJapan

Personalised recommendations